HC Wainwright Issues Positive Forecast for Sana Biotechnology (NASDAQ:SANA) Stock Price

Sana Biotechnology (NASDAQ:SANA) had its price target raised by research analysts at HC Wainwright from $8.00 to $11.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

Several other brokerages have also recently commented on SANA. TD Cowen upgraded Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday. JMP Securities cut shares of Sana Biotechnology from an “outperform” rating to a “market perform” rating in a research report on Tuesday, November 5th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $14.25.

Sana Biotechnology Price Performance

SANA stock opened at $1.65 on Wednesday. The stock has a market cap of $368.39 million, a price-to-earnings ratio of -1.18 and a beta of 1.45. The company has a 50 day simple moving average of $2.38 and a 200 day simple moving average of $4.07. Sana Biotechnology has a 1 year low of $1.52 and a 1 year high of $12.00.

Sana Biotechnology (NASDAQ:SANA) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. On average, equities research analysts anticipate that Sana Biotechnology will post -1.16 EPS for the current fiscal year.

Institutional Trading of Sana Biotechnology

Hedge funds have recently modified their holdings of the stock. Bank of New York Mellon Corp grew its holdings in Sana Biotechnology by 26.5% in the second quarter. Bank of New York Mellon Corp now owns 431,744 shares of the company’s stock worth $2,357,000 after purchasing an additional 90,423 shares during the period. Rhumbline Advisers grew its stake in shares of Sana Biotechnology by 16.0% in the 2nd quarter. Rhumbline Advisers now owns 181,903 shares of the company’s stock valued at $993,000 after buying an additional 25,056 shares during the period. Arizona State Retirement System increased its position in Sana Biotechnology by 36.7% in the 2nd quarter. Arizona State Retirement System now owns 37,028 shares of the company’s stock valued at $202,000 after buying an additional 9,940 shares in the last quarter. XTX Topco Ltd acquired a new position in Sana Biotechnology during the 2nd quarter worth approximately $100,000. Finally, Ensign Peak Advisors Inc bought a new position in Sana Biotechnology in the second quarter worth approximately $372,000. Institutional investors own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.